Prevalence of hereditary antithrombin deficiency (HATD)

HATD, an inherited clotting disorder, carries the highest risk of VTE, yet can be treated by restoring what is missing1

  • HATD affects 1 in every 500 to 5000 individuals2-4
    • This range suggests that approximately 65,000 to 650,000 people in the United States are affected5
  • More than 250,000 patients are hospitalized for VTE each year in the United States6
    • Up to 7500 (3%) of these patients may have HATD1

HATD has 3 distinct features that set it apart from other thrombophilias

Has the highest risk of thrombosis among thrombophilia1

Is the only thrombophilia that can be prevented and treated by replacing the missing AT3

Can be the reason why surgical patients don't have the expected response to their anticoagulation8†

Thrombate+HATD+-+Patient+Brochure

HATD Patient Brochure

Patients who have been diagnosed with HATD may not know how important it is to share this information with their families. This brochure can help them understand their diagnosis.

IMPORTANT SAFETY INFORMATION


THROMBATE III® (antithrombin III [human]) is indicated in patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism.

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays.

In clinical studies, the most common adverse reactions (≥ 5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III.

Please see full Prescribing Information for THROMBATE III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

References: 1. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Crit Rev Clin Lab Sci.2006;43(3):249-290. 2. Patnaik MM, Moll S. Haemophilia. 2008;14(6):1229-1239. 3. THROMBATE III® (antithrombin III [human]) Prescribing Information. Grifols. 4. Wells PS, Blajchman MA, Henderson P, et al. Am J Hematol. 1994;45:321-324. 5. US Census Bureau, Population Division. US and World Population Clocks—POPClocks. www.census.gov/popclock/. Accessed January 23, 2018. 6. Lloyd-Jones D, Adams RJ, Brown TM, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e46-e215. 7. Kottke-Marchant K, Duncan A. Arch Pathol Lab Med. 2002;126:1326-13368. Finley A, Greenberg C. Anesth Anag. 2013;116(6):1210-1222.